Skip to main content
SpringerLink
Log in

Medikamenteninduzierte Dyskinesien

  • Living reference work entry
  • First Online:
Klinische Neurologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 303 Accesses

Zusammenfassung

Während die durch Dopaminrezeptorblocker induzierten akuten Dyskinesien mit Anticholinergika leicht zu behandeln sind und nach Absetzen des induzierenden Medikaments sistieren, ist das Kriterium für die tardive Dyskinesie die Persistenz nach Absetzen der kausativen Pharmaka. Unter der tardiven Dyskinesie lassen sich phänomenologisch mindestens drei eigenständige „tardive“ Syndrome differenzieren: die klassische orobukkolinguale Dyskinesie, die tardive Dystonie und die tardive Akathisie. Bei einem eingetretenen tardiven Syndrom sollte ein Absetzen der Dopaminrezeptorblocker oder eine Umstellung auf das atypische Neuroleptikum Clozapin erwogen werden. Die Therapie der tardiven Syndrome ist weiterhin schwierig. An medikamentösen Ansätzen findet international das nebenwirkungsreiche Tetrabenazin am meisten Beachtung. Für die tardive Dystonie kann der Einsatz von Botulinumtoxin und Anticholinergika in Analogie zur Behandlung der idiopathischen Dystonien erwogen werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Arya DK (1994) Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 165:728–733

    Article  CAS  Google Scholar 

  • Ayd F (1961) A survey of drug induced induced extrapyramidal reactions. JAMA 175:1054–1060

    Article  CAS  Google Scholar 

  • Burke RE, Kang UJ, Jankovic J et al (1989) Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 4:157–175

    Article  CAS  Google Scholar 

  • Citrome LL (2020) Medication options and clinical strategies for treating tardive dyskinesia. J Clin Psychiatry 81(2). pii: TV18059BR2C. https://doi.org/10.4088/JCP.TV18059BR2C

  • Ganzini L, Casey DE, Hoffman WF, McCall AL (1993) The prevalence of metoclopramide-induced tardive dyskinesia and acute extra-pyramidal movement disorders. Arch Intern Med 153:1469–1475

    Article  CAS  Google Scholar 

  • Gunne LM, Haggstrom JE, Sjoquist B (1984) Association of persistent neuroleptic-induced dyskinesia with regional changes in the brain GABA-synthesis. Nature 309:347–349

    Article  CAS  Google Scholar 

  • Jeste DV, Caligiuri MP (1993) Tardive dyskinesia. Schizophr Bull 19:303–315

    Article  CAS  Google Scholar 

  • Kane JM, Smith JM (1982) Tardive dyskinesia. Arch Gen Psychiatry 39:473–481

    Article  CAS  Google Scholar 

  • Loughlin AM, Lin N, Abler V, Carroll B (2019) Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States. PLoS One. 14(6):e0216044. https://doi.org/10.1371/journal.pone.0216044. eCollection 2019

  • Marsden CD, Jenner P (1980) The pathophysiology of extrapyra midal side-effects of neuroleptic drugs. Psychol Med 10:55–72

    Article  CAS  Google Scholar 

  • Nomoto M, Thompson PD, Sheehy MP et al (1987) Anticholinergic-induced chorea in the treatment of focal dystonia. Mov Disord 2:53–56

    Article  CAS  Google Scholar 

  • Raja M (1995) Tardive dystonia. Prevalence, risk factors, and comparison with tardive dyskinesia in a population of 200 acute psychiatric patients. Eur Arch Psychiatry Clin Neurosci 245:145–151

    Article  CAS  Google Scholar 

  • Spiller HA, Hays HL, Aleguas A Jr (2013) Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs 27(7):531–543

    Google Scholar 

  • Steele J, Faulds D, Sorkin EM (1993) Tiapride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation. Drugs Aging 3:460–478

    Article  CAS  Google Scholar 

  • Sweet C (1975) Drug induced dystonia. Am J Psychiatry 132:532–533

    Article  Google Scholar 

  • Tripathi R, Reich SG, Scorr L, Guardiani E, Factor SA (2019) Lurasidone-induced tardive syndrome. Mov Disord Clin Pract 6(7):601–604. https://doi.org/10.1002/mdc3.12812. eCollection 2019 Sep

  • Vijayakumar D, Jankovic J (2016) Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs 76(7):779–87

    Google Scholar 

  • Yim SH, Choi YH, Heo K, Cho KH (2019) A case of dyskinesia after levetiracetam administration. BMC Neurol 19(1):292. https://doi.org/10.1186/s12883-019-1519-8

Download references

Author information

Authors and Affiliations

  1. Neurologie und klinische Neurophysiologie, Schön Klinik München Schwabing, München, Deutschland

    Andrés Ceballos-Baumann

Authors
  1. Andrés Ceballos-Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrés Ceballos-Baumann .

Editor information

Editors and Affiliations

  1. Essen, Germany

    Peter Berlit

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Ceballos-Baumann, A. (2018). Medikamenteninduzierte Dyskinesien. In: Berlit, P. (eds) Klinische Neurologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44768-0_133-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-44768-0_133-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-44768-0

  • Online ISBN: 978-3-662-44768-0

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation